ASCO 2011: Key head and neck cancer research
22 Jun 2011
ASCO 2011: Key head and neck cancer research
New oncogene target for breast cancer: LMTK3
Olaparib maintenance therapy for ovarian cancer and updates from ICON7
The ENERGY trial
Advances in breast cancer research from ASCO 2011
PTEN expression does not diminish trastuzumab effectiveness
Combining oral targeted therapies shows early anti-tumour activity for advanced melanoma
Vall d´Hebron Institute of Oncology; advancing personalized and targeted therapies against cancer
Translational research from the Vall d'Hebron Institute of Oncology
Cancer prevention through education
Highlights from 2011 and ASCO’s future
Future for immunotherapies